MedTrace Logo

Outcomes of 36 vs 38 Hour Intervals From Ovulation Trigger To Oocyte Pick-Up:A Multi-Center Randomized Controlled Trial

NCT05803655 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2023-10-05

No results posted yet for this study

Summary

Women who undergo assisted reproduction technology (ART) treatment will be eligible for this study. The goal of this randomized clinical trial is to compare the outcomes of ART treatment between women who have 36 and 38 hours interval between the administration of ovulation trigger (ovulation trigger medication initiates oocyte maturation and makes it possible for the egg to be collected by aspiration, during a procedure called oocyte pick-up, OPU) and OPU. The main questions it aims to answer are, does prolonging the trigger-OPU interval to 38-hours improve:

1. Primarily:

•Ratio of metaphase-2 oocytes to total number of follicles
2. Secondarily:

* Maturation rate
* Fertilization rate
* Blastulation rate
* Premature ovulation rate
* Positive pregnancy test rate
* Clinical pregnancy rate
* Live birth rate

compared to 36-hours interval?

Conditions

Interventions

OTHER

36-hour duration between ovulation triggering and oocyte pick-up procedure

36-hour duration between ovulation triggering and oocyte pick-up procedure

OTHER

38-hour duration between ovulation triggering and oocyte pick-up procedure

38-hour duration between ovulation triggering and oocyte pick-up procedure

Sponsors & Collaborators

  • Turkish Society of Reproductive Medicine

    collaborator UNKNOWN

  • Koç University

    lead OTHER

Principal Investigators

  • Engin Turkgeldi, Assoc. Prof · Koç University

  • Baris Ata, Prof.Dr · Koç University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2024-09-30
Completion
2025-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05803655 on ClinicalTrials.gov